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Abstract
Introduction: Several reports have found the onset or activity of inflammatory myopathies to show spatial
clustering and seasonal association. We recently detected autoantibodies against melanoma differentiation-
associated gene 5 (MDA-5) in more than 20% of patients with dermatomyositis. Anti-MDA-5 antibodies were
associated with the presence of rapidly progressive interstitial lung disease in clinically amyopathic dermatomyositis
(CADM). The present study aims to assess the growing prevalence of CADM and the geographical incidence of
anti-MDA-5-positive patients.
Methods: We reviewed medical charts and examined the presence of anti-MDA-5 antibodies in 95 patients,
including 36 CADM patients. Sera were obtained from 1994 through 2011. Statistical analyses were performed to
assess whether CADM development and the presence of anti-MDA-5 antibodies were associated with various
parameters, including age at disease onset, season of onset, annual positivity, and population of resident city.
Results: Tertiles based on the year when the sera were collected showed increasing tendencies of CADM and anti-
MDA-5-positive patients among all of the dermatomyositis patients. From 1994 to 2010, the relative prevalence of
CADM and anti-MDA-5 antibody-positive patients significantly increased. Interestingly, the presence of anti-MDA-5
antibodies in 26 patients was inversely associated with the population of their city of residence.
Conclusions: This is the first study to examine the distribution of anti-MDA-5-positive dermatomyositis phenotypes
in Japan. Regional differences in the incidences of these phenotypes would suggest that environmental factors
contribute to the production of antibodies against MDA-5, which triggers innate antiviral responses.
Introduction
Idiopathic inflammatory myopathies are a heterogeneous
group of autoimmune disorders that target the skeletal
muscle and skin. Disease-related death is generally asso-
ciated with malignancy and interstitial lung disease. The
most frequent forms, polymyositis and dermatomyositis
(DM), are thought to result from environmental expo-
sure that leads to immune activation in genetically sus-
ceptible individuals. Several reports have found the
onset or activity of inflammatory myopathies to show
spatial clustering and seasonal association [1-5].
A subgroup of DM patients who have typical skin
manifestations of DM but little evidence of myositis has
been recognized as clinically amyopathic dermatomyosi-
tis (CADM) [6]. Although it is still undetermined
whether CADM is a distinct clinical entity or just an
early phase of classic DM, rapidly progressive interstitial
lung disease (ILD) can occur in CADM patients, espe-
cially in East Asia [7]. This patient subset with CADM
and rapidly progressive ILD has been shown to have
specific autoantibodies, originally called anti-CADM-140
antibodies [8]. The target autoantigen is melanoma dif-
ferentiation-associated gene 5 (MDA-5) [9-11], which
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ing RNA virus infections [12].
To better understand this subset of patients, it is
important to examine the epidemiologic characteristics
of CADM patients with anti-MDA-5 antibodies, whose
outcome is often fatal. According to our clinical experi-
ences, we have recently noticed that the prevalence of
CADM patients with anti-MDA-5 antibodies seems to
be growing, particularly in rural areas. We therefore
examined the epidemiologic features of CADM and




We reviewed medical charts and examined the presence
of anti-MDA-5 antibodies in 95 Japanese patients (one
of them a half-Japanese, half-Filipino boy) with DM,
including 36 patients with CADM, 15 patients with can-
cer-associated DM and 44 patients with classical DM,
who were seen by or consulted the Department of Der-
matology at Nagoya University Graduate School of Med-
icine from 1994 to 2011. These patients were diagnosed
with DM or CADM based on the criteria of Bohan et
al. [13] or Sontheimer [6], respectively. In general,
CADM presents as typical skin lesions and amyopathy
or hypomyopathy that lasts for more than 6 months.
The CADM group included patients who developed
fatal ILD within the first 6 months after disease onset.
Since juvenile DM with rapidly progressive ILD and/or
anti-MDA-5 antibodies has been reported in Japan
[7,11,14], patients who manifested the disease at < 18
years of age were also included. Patients who were ori-
ginally seen at other hospitals far outside our area and
who then transferred to our hospital were excluded
from the present study. Serum samples were obtained
from all of the patients between 1 October 1994, the
date when we began to build a serum bank of autoim-
mune rheumatic disease patients, and 30 June 2011. The
population data on city of residence in 2010 were
obtained from web data published by public offices in
25 cities, eight counties and one village.
The present study was approved by the Ethics Com-
mittee of Nagoya University Graduate School of Medi-
cine. This study meets and is in compliance with all
ethical standards in medicine. Informed consent includ-
ing that for publication of the study was obtained from
all patients according to the Declaration of Helsinki.
Immunoprecipitation
Anti-MDA-5 antibodies were screened by an immuno-
precipitation assay using biotinylated recombinant
MDA-5 produced from full-length MDA-5 cDNA using
the TnT
® T7 Quick Coupled Transcription/Translation
System (Promega, Madison, WI, USA) and the Trans-
cend
™ Colorimetric Non-Radioactive Translation Detec-
tion System (Promega), according to our published
protocol [11]. This method was confirmed to produce
consistent results based on a standard immunoprecipita-
tion assay using
35S-methionine-labeled cell extracts
[11]. Serum samples from 82 patients were already char-
acterized in our previous report [11]. All serum samples
were stored at -70°C until the experiments.
Statistical analysis
The subjects were divided into tertiles based on year the
sera were collected, age at collection, age at onset, or
population of the city of residence, separately, to exam-
ine the associations between each of these factors and
the development of CADM and the presence of anti-
MDA-5 antibodies. The differences and linear trends
across the tertiles were assessed using the chi-square
test and the Cochran-Armitage trend test, respectively.
SPSS version 17.0 for Windows (SPSS Japan Inc.,
Tokyo, Japan) was used to perform the statistical analy-
sis. P < 0.05 was considered significant.
Results
Patient population
Between 1 October 1994 and 30 June 2011, sera from 95
patients with DM were collected. During 1994 sera were
drawn from 24 patients, two-thirds of whom had been
diagnosed with DM and treated by our department. The
mean age at onset was 46.9 years (range: 1 to 80 years)
and that at the time of sera collection was 50.2 years
(range: 3 to 84 years). There were 67 (70.5%) female
patients. Ten patients developed the disease under 18
years of age.
A review of the medical records indicated that 36
patients (28/36, 77.8% female; 5/36, 13.9% juvenile) had
CADM. For these 36 patients, the mean age at onset
was 44.9 years (range: 1 to 73 years) and that at the
time of sera collection was 48.2 years (range: 3 to 84
years). Based on the immunoprecipitation assays, 26
patients (21/26, 80.8% female; 1/26, 3.8% juvenile) had
anti-MDA-5 antibodies. For these 26 patients, the mean
age at onset was 46.8 years (range: 11 to 66 years) and
that at the time of sera collection was 48.2 years (range:
11 to 71 years). Twenty-five patients with anti-MDA-5
antibodies were diagnosed as CADM, and the remaining
patient met the criteria for classical DM. All but one of
our patients with anti-MDA-5 antibodies had ILD.
To grasp the overall trend, tertile analysis was con-
ducted based on the number of cases for all patients
with DM as well as for patients with CADM and those
with anti-MDA-5 antibodies (Table 1). The mean ages
at onset and at the time of sera collection did not signif-
icantly differ among the tertiles (data not shown), but
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patients significantly increased from the first to the
third periods of the study.
Annual prevalence of CADM and anti-MDA-5 antibodies
S i n c em a n yo ft h ep a t i e n t sw h o s es e r aw e r ed r a w ni n
1 9 9 4h a db e e nt r e a t e da to u rh o s p i t a l ,t h ea b o v et e r t i l e
analysis was partially biased. Before the sampling in
1994 there may have been some fatal cases of rapidly
progressive ILD. Moreover, some CADM patients
stopped seeing their doctors due to minor illness. In
light of these possibilities, we analyzed only the 72
patients who manifested the disease after 1994, in order
to investigate the growing trend of CADM and anti-
MDA-5-positive patients (Figure 1). The relative
prevalence of both CADM anda n t i - M D A - 5 - p o s i t i v e
patients among all DM patients was found to have sig-
nificantly increased (P =0 . 0 2 9a n dP = 0.044,
respectively).
Geographical incidence of dermatomyositis patients with
anti-MDA-5 antibodies
Our university hospital is in Nagoya (population 2.2 mil-
lion), the biggest city in central Japan. To clarify the
regional differences in a subgroup of patients, we com-
pared the prevalence of CADM and anti-MDA-5-posi-
tive patients by tertiles based on the population of the
patient’s city of residence (Table 2), and we plotted the
anti-MDA-5-positive patients on a map (Figure 2).
Interestingly, CADM patients were less prevalent in



















32 (12:20) 47.5 (4 to 80) 6 (18.8%) (2:4) P for
difference =
0.012
45.5 (4 to 73) 2 (6.3%) (1:1%) P for
difference =
0.003
53 (43 to 63)
T2 (1996 to
2003)
30 (6:24) 50.1 (15 to 79) 12 (40.0%) (1:11) P for trend
= 0.003
50.7 (20 to 73) 10 (33.3%) (0:10) P for trend
= 0.001
48.9 (20 to 66)
T3 (2004 to
2011)
33 (10:23) 43.6 (1 to 73) 18 (54.5%) (5:13) 40.8 (1 to 69) 14 (42.4%) (4:10) 44.4 (11 to 58)
CADM, clinically amyopathic dermatomyositis; DM, dermatomyositis; M:F, male:female; MDA-5, melanoma differentiation-associated gene 5. *Prevalence of CADM
in total DM. **Prevalence of anti-MDA-5 in total DM.
Figure 1 Annual prevalence of patients with clinically amyopathic dermatomyositis or anti-melanoma differentiation-associated gene
5 antibodies. The regression equation is shown, in which the year of disease onset is defined as 1994 = 1, 1995 = 2,..., 2010 = 17 on the x axis
and the presence or absence of clinically amyopathic dermatomyositis (CADM) or anti-melanoma differentiation-associated gene 5 (anti-MDA-5)
antibodies is defined as 1 and 0, respectively, on the y axis (P for linear trend).
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Page 3 of 6urban areas, but this association was only marginally
significant, whereas there were significantly more anti-
MDA-5-positive patients in rural areas than in urban
ones. Areas northeast and far northwest of Nagoya con-
tained particularly high numbers of patients with anti-
MDA-5 antibodies: 10 patients in the northeast, and five
patients in the northwest (Figure 2, circular dotted
area). These areas had nine and six CADM patients in
the northwest and northeast, respectively. All 15
patients with anti-MDA-5 antibodies were natives of the




















P value** Mean age at
onset
(range)












T2 (130 to 826) 26 (7:19) 44.0 (9 to 80) 10 (38.5%) (3:7) P for trend
= 0.031




T3 (2,200) 38 (17:21) 47.3 (1 to 79) 10 (26.3%) (4:6) 45.9 (1 to 73) 5 (13.2%) (1:4) 51.0 (39 to
63)
CADM, clinically amyopathic dermatomyositis; DM, dermatomyositis; M:F, male:female; MDA-5, melanoma differentiation-associated gene 5. *Prevalence of CADM
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Figure 2 Geographic distribution of patients with dermatomyositis. A residential area of 95 patients was plotted. NGY, Nagoya city. Red and
white circles show patients with and without anti-melanoma differentiation-associated gene 5 (anti-MDA-5) antibodies, respectively. Blue line
shows the Kiso River, which is the biggest in the area.
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the disease in 2002 and 2010, respectively. Notably, five
of the six patients with anti-MDA-5 antibodies whose
disease began in 2002 and all four of the patients with
anti-MDA-5 antibodies whose disease began in 2010
were from these two areas (Figure 1).
Seasonal onset
The information on seasonality of disease onset was
available for 78 patients, including 33 CADM and 25
anti-MDA-5-positive patients. There were no significant
seasonal patterns of disease onset in the overall patient
group or in the subgroups of male, female, CADM or
anti-MDA-5-positive patients (data not shown). How-
ever, the incidence of anti-MDA-5 antibodies in areas
with populations under 108 × 10
3, but not in areas with
populations over 130 × 10
3, was the highest in autumn
(onset in autumn in areas with populations under 108 ×
10
3 vs. onset in autumn in areas with populations over
130 × 10
3 = 8/14 vs. 1/11, P = 0.033).
Discussion
A Japanese multicenter study confirmed recently that
patients with anti-MDA-5 antibodies frequently have
CADM with rapidly progressive ILD and a poor prog-
nosis [15]. With increasing awareness of the CADM dis-
ease subtype, which was proposed by Sontheimer in the
1990s, we felt not only that the prevalence of CADM is
increasing but also that more CADM patients with anti-
MDA-5 antibodies have recently been coming from rural
areas than from urban ones. To examine these matters
statistically, we investigated the prevalence of CADM and
anti-MDA-5 antibodies among all of the DM patients.
Because the present study was neither population
based nor community based, it is difficult to say that the
incidence of CADM is increasing. However, the fre-
quency of anti-MDA-5 antibodies among all DM
patients is increasing. Although this autoantibody was
only recently characterized [8,9], our initial study found
that the serum collected from one patient in 1994 was
anti-MDA-5 antibody-positive. Contrary to the increas-
ing prevalence of anti-MDA-5 antibodies, other types of
autoantibodies appear to be decreasing. We also charac-
terized the prevalence of anti-transcriptional intermedi-
ary factor-1g antibodies among all patients examined in
this study. These antibodies, however, which were
detected in 12 patients, showed no significant epidemio-
logical characteristics under the same analysis (data not
shown). In our previous study using traditional immu-
noprecipitation experiments, we did not detect signifi-
cant decreases in the prevalence of any specific
autoantibodies [11]. There is little possibility that the
long storage of the sera caused the autoantibodies to
become less active, however, because various kinds of
DM/polymyositis-specific autoantibodies were found in
many of the sera that were drawn in 1994 and 1995
(two patients with anti-transcriptional intermediary fac-
tor 1g, two patients with anti-MJ, two patients with
anti-PL-7, one patient with anti-Jo-1, one patient with
anti-EJ and one patient with anti-KS; our unpublished
observations), along with the anti-MDA-5 antibodies
found in the two other patients during this period.
MDA-5 detects some viruses, including picornaviruses,
and is involved in the host defense response to infection.
Antibodies to coxsackievirus B, a picornavirus, were pre-
viously reported to be prevalent in patients with juvenile
DM [16]. Although we could not find an epidemiologic
study on the environmental levels of picornavirus in our
district, the seasonal distribution of viruses in the river
water in Nara Prefecture, which is also in central Japan,
has been examined [17]. The coxsackievirus B levels
peaked there in the summer, and the virus continued to
be detected in the autumn and winter. Interestingly,
there was a marked increase in the prevalence of anti-
MDA-5 antibodies in our study in areas northeast and
northwest of Nagoya (Figure 2). These regions are on
the Kiso River, which is the biggest river in our area
(blue line in Figure 2). In these areas, there was also an
accumulation of CADM. It is unlikely that sun exposure
strongly contributed to the pathogenesis, because the 15
patients with CADM included only one outdoor worker.
The present study has several limitations because of
t h es m a l ln u m b e ro fs t u d ys u b j e c t s .T h et i m el a g
between the initial presentation of disease and the clini-
cal assessment should be considered. The interval
between disease onset and the time of sera collection in
this study was not significantly different, however,
between patients with and without CADM, between
patients with and without anti-MDA-5 antibodies, or
among the tertiles depicted in Table 1 (data not shown),
suggesting that the patient follow-up periods did not
differ by disease subtype. Since people in rural areas
generally have reduced access to specialists, patients
with severe illness, such as anti-MDA-5-positive
patients, might be more prevalent in rural areas than in
urban areas. Moreover, medical practices at a university
hospital have an inherent referral bias.
Many reports have suggested that environmental factors
play a role in the development of DM and the production
of myositis-related autoantibodies (reviewed in [18]). No
single factor, however, can explain that development and
that production, and the possible growing prevalence of
CADM and anti-MDA-5-positive patients. It seems diffi-
cult to identify environmental factors that possibly
increase the annual prevalence of CADM and anti-MDA-
5-positive patients, because patients could have several
environmental exposures that have possible interrelation-
ships with genetic risk factors. Various environmental
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to determine which are associated with disease onset and
whether these play any role in etiology.
To our knowledge, this is the first epidemiologic study
on anti-MDA-5 antibodies. Although it is difficult to
draw strong conclusion from a single cohort study, epi-
demiologic studies play an important role in disease
assessment. These studies determine the extent of dis-
ease and the natural history within a community, iden-
tify potential etiologic factors and enhance our
understanding of disease pathogenesis.
Conclusions
Clinically amyopathic dermatomyositis might be growing
in prevalence with the increase of anti-MDA-5 antibody-
positive patients in central Japan. Regional differences in
the incidences of the anti-MDA-5 antibody would sug-
gest that environmental factors contribute to the produc-
tion of autoantibodies against MDA-5. It will be
important to conduct larger population-based studies
through multicenter collaboration using DM-specific
autoantibodies to define patient groups and clarify the
disease etiology associated with environmental factors.
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